English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

These studies evaluated the 24-h forced expiratory volume in 1 sec (FEV 1 ) profile of once-daily (QD) olodaterol compared to placebo and twice-daily (BID) formoterol in patients with moderate to very severe chronic obstructive pulmonary disease. In two replicate, randomized, double-blind, double-dummy, four-way crossover studies, patients received olodaterol 5 and 10 μg QD, formoterol 12 μg BID, or placebo for 6 weeks in addition to usual-care background maintenance therapy. Co-primary end points were FEV 1  area under the curve from 0–12 h (AUC 0–12 ) response (change from baseline) and FEV 1  AUC from 12–24 h (AUC 12–24 ) response after 6 weeks, with FEV 1  AUC from 0–24 h response identified as a key secondary end point. Other secondary end points included FEV 1  AUC from 0–3 h and trough FEV 1  responses, as well as corresponding forced vital capacity responses. With both olodaterol doses, FEV 1  increased to near-maximal 30 min post-morning dose, which was sustained over 24 h. FEV 1  also increased within 30 min post-morning dose of formoterol and was sustained over 12 h; the second formoterol dose resulted in a further increase, sustained for an additional 12 h. FEV 1  AUC 0–12  and AUC 12–24  responses with both QD olodaterol doses and BID formoterol were significantly greater than placebo at 6 weeks ( P  < .0001). Secondary end-point outcomes were consistent with those of the co-primary end points. These data, together with those from the wider phase III clinical program, provide evidence for the 24-h bronchodilator efficacy of olodaterol QD in this patient population.    Trial registry  ClinicalTrials.gov;  NCT00931385  and  NCT00932646 .    Electronic supplementary material  The online version of this article (doi:10.1186/2193-1801-3-419) contains supplementary material, which is available to authorized users.

springerplus

The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies